Non-Hodgkin’s lymphoma of mantle cell: Case Report

• Autor(a) principal: El Kik, Maron
• Data de Publicação: 2010
• Outros Autores: de Freitas, Antônio de Pádua, Souto Filho, João Tadeu Damian, Barbosa, Aline Alves, Paes da Silva, Aline Maria Rios, Barbosa, Fernanda Alves, Ribas, Gustavo Fernandes
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Científica da Faculdade de Medicina de Campos
• Texto Completo: https://www.fmc.br/ojs/index.php/RCFMC/article/view/120
• topic: Linfoma; Linfoma não-Hodking; neoplasia; células do manto; Lymphoma; Non-Hodgkin’s Lymphoma; neoplasm; mantle cell

Introduction: Lymphomas are one group of malignancies originating in lymphoid tissue and the mantle cell lymphoma is a subtype of non-Hodgkin’s lymphoma (NHL) derived from small “virgin” B lymphocytes of the mantle zone. It corresponds to 6% of all NHL. Objective: To describe a case of non-Hodgkin´s lymphoma mantle cell. Method: Review of medical records. Case Report: J.N.A, 62 years old, male, with a history of painless left cervical lymphadenopathy, followed by the appearance of right and left axillary, bilateral inguinal and supraclavicular limphadenopathies, and painless enlargement of the scrotum. He reported night sweats, followed by asthenia and weight loss. On examination: firm lymph nodes adhered to deep planes, elastic consistency. Abdomen: distended, depressing, painless to superficial and deep palpation, presenting hepatosplenomegaly. Chest radiograph presenting bilateral mediastinal lymphadenopathy. The diagnoses was made by cervical lymph node biopsy: non-Hodgkin’s lymphoma of mantlecell, showing immunohistochemistry with positive CD20 and Cyclin D1. Iliac bone marrow biopsy on the right and left: diffuse infiltration by non-Hodgkin’s small cells, consistent with mantle cell lymphoma, representing 90% of the total cellularity. It was accomplished steroid pulse therapy and after, initiated chemotherapy with CHOP scheme. At this moment, he is in multidisciplinary follow. Conclusion: This case portrays an aggressive lymphoma with disseminated disease (stage IV of Ann Harbor) and prognostic index (IPI) with high scores indicating a worse prognosis. In these cases the treatments have been unsatisfactory, with complete remission achieved by a minority, with median survival of 3 to 5 years.